iBio Inc. [AMEX: IBIO] stock went on a downward path that fall over -4.03% on Tuesday, amounting to a one-week price increase of more than 4.38%. The company report on May 20, 2021 that iBio to Present at the UBS Global Healthcare Virtual Conference.
iBio, Inc. (NYSE:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced that management will present an update on the Company’s business at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 4:00 p.m Eastern Time.
The presentation will be webcast live and archived on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section.
Over the last 12 months, IBIO stock dropped by -12.80%. The one-year iBio Inc. stock forecast points to a potential upside of 42.8. The average equity rating for IBIO stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $303.02 million, with 215.54 million shares outstanding and 213.86 million shares in the current float. Compared to the average trading volume of 10.84M shares, IBIO stock reached a trading volume of 3543792 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on iBio Inc. [IBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBIO shares is $2.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBIO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for iBio Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 22, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on June 26, 2020, representing the official price target for iBio Inc. stock.
The Average True Range (ATR) for iBio Inc. is set at 0.14, with the Price to Sales ratio for IBIO stock in the period of the last 12 months amounting to 101.01. The Price to Book ratio for the last quarter was 2.92, with the Price to Cash per share for the same quarter was set at 0.49.
IBIO Stock Performance Analysis:
iBio Inc. [IBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.38. With this latest performance, IBIO shares gained by 5.93% in over the last four-week period, additionally sinking by -11.18% over the last 6 months – not to mention a drop of -12.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBIO stock in for the last two-week period is set at 48.67, with the RSI for the last a single of trading hit 48.42, and the three-weeks RSI is set at 48.27 for iBio Inc. [IBIO]. The present Moving Average for the last 50 days of trading for this stock 1.4732, while it was recorded at 1.4380 for the last single week of trading, and 1.7334 for the last 200 days.
Insight into iBio Inc. Fundamentals:
iBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.60 and a Current Ratio set at 17.70.
iBio Inc. [IBIO] Insider Position Details
There are presently around $63 million, or 20.60% of IBIO stock, in the hands of institutional investors. The top three institutional holders of IBIO stocks are: BLACKROCK INC. with ownership of 15,432,756, which is approximately 33.328% of the company’s market cap and around 0.30% of the total institutional ownership; VANGUARD GROUP INC, holding 10,562,633 shares of the stock with an approximate value of $15.11 million in IBIO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $4.79 million in IBIO stock with ownership of nearly 35.608% of the company’s market capitalization.
56 institutional holders increased their position in iBio Inc. [AMEX:IBIO] by around 14,936,776 shares. Additionally, 32 investors decreased positions by around 985,444 shares, while 22 investors held positions by with 28,422,350 shares. The mentioned changes placed institutional holdings at 44,344,570 shares, according to the latest SEC report filing. IBIO stock had 17 new institutional investments in for a total of 373,168 shares, while 16 institutional investors sold positions of 290,348 shares during the same period.